Health and Healthcare

Arena Pharmaceuticals, Inc. : ARNA

All ARNA Articles

117 Articles

Jon C. Ogg | Jan 22, 2013 at 1:21 PM EST

Arena Risk: Possible Drag on All Weight-Loss Drugs

ThinkstockArena Pharmaceuticals Inc. (NASDAQ: ARNA) is posing yet one more threat to ambitious biotechs and drug-makers who are targeting the…

Jon C. Ogg | Jan 16, 2013 at 8:16 AM EST

The Obesity Drug Stock Rally Has Started (OREX, ARNA, VVUS, BAC)

ThinkstockBack in December, we took an in-depth look at what has become a crowded race in the obesity drug market.…

Paul Ausick | Dec 31, 2012 at 1:05 PM EST

Searching for Profits: Top Ticker Searches for 2012

ThinkstockSome of the biggest business stories of the past year drew the most Internet search traffic to the newsmakers, which…

Jon C. Ogg | Dec 18, 2012 at 10:43 AM EST

Is There Finally a Winner in the Crowded Obesity Drug Market?

ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

Trey Thoelcke | Nov 12, 2012 at 8:04 AM EST

Short Interest in Biotech Remains Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ:…

Trey Thoelcke | Oct 25, 2012 at 7:41 AM EDT

Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ:…

Trey Thoelcke | Oct 11, 2012 at 8:25 AM EDT

Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September…

Trey Thoelcke | Sep 26, 2012 at 8:53 AM EDT

Short Interest in Biotech on the Rise (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short…

Trey Thoelcke | Sep 13, 2012 at 8:52 AM EDT

Short Interest in Biotech Wanes (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date…

Jon C. Ogg | Sep 6, 2012 at 8:15 AM EDT

Top Analyst Upgrades and Downgrades (ATVI, ARNA, BCS, EAT, CIT, CLF, ESRX, MWW, NBR, NOK, NVO, OREX, PBY, GOLD, SWK, STI, VPRT, KEY)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Thursday.…

Trey Thoelcke | Aug 27, 2012 at 8:10 AM EDT

Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date…

Jon C. Ogg | Jul 18, 2012 at 9:05 AM EDT

Weight Loss Drugs Eating Up FDA Approval

The history of weight loss drugs is sketchy at best. But VIVUS Inc. (NASDAQ: VVUS) is making up on all…

Jon C. Ogg | Jul 16, 2012 at 10:43 AM EDT

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to…

Jon C. Ogg | Jul 10, 2012 at 7:35 AM EDT

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks…

Jon C. Ogg | Jul 2, 2012 at 2:42 PM EDT

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value…

1 2 3 4 5 6 … 8

Arena Pharmaceuticals, Inc. : ARNA

All ARNA Articles

Arena Risk: Possible Drag on All Weight-Loss Drugs

The Obesity Drug Stock Rally Has Started (OREX, ARNA, VVUS, BAC)

Searching for Profits: Top Ticker Searches for 2012

Is There Finally a Winner in the Crowded Obesity Drug Market?

Short Interest in Biotech Remains Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech on the Rise (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech Wanes (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Top Analyst Upgrades and Downgrades (ATVI, ARNA, BCS, EAT, CIT, CLF, ESRX, MWW, NBR, NOK, NVO, OREX, PBY, GOLD, SWK, STI, VPRT, KEY)

Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

Weight Loss Drugs Eating Up FDA Approval

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Arena Pharmaceuticals, Inc. : ARNA

All ARNA Articles

Arena Risk: Possible Drag on All Weight-Loss Drugs

The Obesity Drug Stock Rally Has Started (OREX, ARNA, VVUS, BAC)

Searching for Profits: Top Ticker Searches for 2012

Is There Finally a Winner in the Crowded Obesity Drug Market?

Short Interest in Biotech Remains Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech Is Mixed (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech on the Rise (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Short Interest in Biotech Wanes (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS, IBB)

Top Analyst Upgrades and Downgrades (ATVI, ARNA, BCS, EAT, CIT, CLF, ESRX, MWW, NBR, NOK, NVO, OREX, PBY, GOLD, SWK, STI, VPRT, KEY)

Biotech: Vertex and VIVUS Draw Short Interest (ALXN, AMGN, ARNA, BIIB, CELG, DNDN, GILD, ILMN, ONXX, PCYC, REGN, VRTX, VVUS)

Weight Loss Drugs Eating Up FDA Approval

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

Which Biotechs Could Be Next M&A Targets (AMLN, BMY, VRTX, CELG, CBST, AMRN, BMRN, VVUS, ARNA, PCYC, AFFX, THRX, RIGL, HGSI, GSK, DNDN)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s